<\/p>
Emcure Pharmaceuticals has entered the first year of its five-year strategic plan, with international markets and margin expansion supporting performance, even as its domestic business undergoes structural changes.<\/p>
The Pune-headquartered drugmaker, which reported revenue of over $1 billion for FY26, is strengthening its pipeline in complex injectables and biosimilars, alongside expanding its presence in regulated markets such as Europe and Canada.<\/p>
\u201cIn FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth,\u201d said Satish Mehta, CEO and Managing Director of the company. He added that international markets demonstrated robust momentum, while the company remains focused on \u201csustainable, above-industry growth and consistent margin expansion.\u201d<\/p>
Emcure\u2019s international business grew 22.2% year-on-year to \u20b95,177 crore in FY26, outpacing its domestic segment, which rose 10% to \u20b94,027 crore. Growth in overseas markets was driven by expansion in the base business and new product launches across regions, including Europe and Canada.<\/p>
The company also expanded through strategic deals during the year. It completed a minority stake buyout in Zuventus Healthcare and executed bolt-on acquisitions in the UK and Canada, alongside in-licensing arrangements to strengthen its portfolio.<\/p>
Its pipeline in complex injectables and biosimilars remains a key driver of future growth, the company said.<\/p>
However, the domestic business saw relatively softer performance in the March quarter, with growth impacted by portfolio and team reorganisation linked to the Zuventus integration.<\/p>
For FY26, Emcure reported revenue from operations of \u20b99,204 crore, up 16.6% year-on-year and ahead of its stated guidance. EBITDA rose 21.8% to \u20b91,789 crore, with margins improving to 19.4%.<\/p>
Profit after tax stood at \u20b9941 crore, up 33.1%, while adjusted PAT increased 40.9% to \u20b91,008 crore.<\/p>
In the fourth quarter, revenue grew 16.7% year-on-year to \u20b92,470 crore. EBITDA rose 24.5% to \u20b9485 crore, while adjusted PAT increased 36% to \u20b9279 crore.<\/p> <\/div>
Emcure, drugs manufacture, injectables, biosimilars#Emcure #expands #global #business #bets #complex #drugs #pipeline1778018337<\/p> ","protected":false},"excerpt":{"rendered":"
Emcure Pharmaceuticals has entered the first year of its five-year strategic plan, with international markets and margin expansion supporting performance, even as its domestic business undergoes structural changes. The Pune-headquartered drugmaker, which reported revenue of over $1 billion for FY26, is strengthening its pipeline in complex injectables and biosimilars, alongside expanding its presence in regulated […]<\/p>\n","protected":false},"author":1,"featured_media":3429,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[4103,28037,261,3194,3648,28035,14748,972,187,28036,6987],"class_list":["post-7555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-content-marketing","tag-bets","tag-biosimilars","tag-business","tag-complex","tag-drugs","tag-drugs-manufacture","tag-emcure","tag-expands","tag-global","tag-injectables","tag-pipeline"],"acf":[],"_links":{"self":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/7555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7555"}],"version-history":[{"count":0,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/7555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/media\/3429"}],"wp:attachment":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7555"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}